Content about Meda

SOLNA, Sweden — Meda announced Friday that it has signed an agreement to acquire MidNite, an OTC sleep-aid product. MidNite is well established in the U.S. and holds a market leading position within a growing category. Transaction terms were not disclosed.

“This acquisition enhances our presence in the U.S. ahead of other future OTC launches," stated Anders Lönner, CEO of Meda. 

Annualized revenues for MidNite are approximately $15 million, the company reported. 

ATLANTA — Meda Consumer Healthcare last week featured three revitalized Feosol SKUs, which are set to launch at retail in May, at the ECRM Vitamin, Diet & Sports Nutrition EPPS conference.

The lineup lends itself to a good-better-best merchandising strategy in what has been a commoditized category, and the marketing plan in place to support the launch will mean a significant uptick in promotion of iron supplementation.

MISSISSAUGA, Ontario — Canadian drug maker Valeant Pharmaceuticals International will acquire rights to topical drugs for eczema and cold sores from Swedish drug maker Meda.

Valeant said it would buy rights for the eczema drug Elidel (pimecrolimus) and the cold sore drug Xerese (acyclovir and hydrocortisone) for the United States, Canada and Mexico. Valeant said, however, that Xerese has not yet received regulatory approval in Canada.

ATLANTA — Meda Consumer Healthcare recently was named the grand winner of the MAX Awards for excellence in marketing for the relaunch of Bifera, an over-the-counter supplement that offers two types of iron — protein- and plant-based.

Presented by Georgia State University's Robinson College of Business Department of Marketing and the Atlanta Business Chronicle, the MAX Awards honored outstanding marketing innovations developed or launched by Georgia companies in 2010.

Many generic drug companies have long marketed branded drugs on the side, but lately, some branded drug companies have sought to enter the generics business as well. One of those companies is Meda Pharmaceuticals, the U.S. subsidiary of Swedish drug maker Meda AB. Drug Store News recently interviewed John White, Meda’s senior director of marketing.

Drug Store News: What gave Meda the idea of pursuing generics?

SOMERSET, N.J. A lot of generic drug companies have conducted business in the branded drug market on the side for a long time, with Teva Pharmaceutical Industries and Watson Pharmaceuticals standing out as good examples. But lately, some branded drug companies have sought to get into generics as well.

Meda Pharmaceuticals, the U.S. subsidiary of Swedish drug maker Meda A.B., recently decided to create its own generics subsidiary, calling it Wallace Pharmaceuticals, senior marketing director John White told Drug Store News.